Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15200MR)

This product GTTS-WQ15200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15200MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14509MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ8698MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ9977MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ14357MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ4672MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ5337MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ10260MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ8455MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW